Lack of durable cross-neutralizing antibodies against zika virus from dengue virus infection

Emerging Infectious Diseases

Volumn 23, Issue 5, 2017, Pages 773-781

  Collins, Matthew H ^a   McGowan, Eileen ^a   Jadi, Ramesh ^a   Young, Ellen ^a   Lopez, Cesar A ^a   Baric, Ralph S ^a   Lazear, Helen M ^a   de Silva, Aravinda M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORSERADISH PEROXIDASE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; ANTISERUM; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CROSS REACTION; DENGUE; DENGUE VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE STATUS; OPTICAL DENSITY; PLAQUE ASSAY; POLYACRYLAMIDE GEL ELECTROPHORESIS; ULTRACENTRIFUGATION; VIRUS NEUTRALIZATION; ZIKA VIRUS; ANIMAL; CELL LINE; CLASSIFICATION; IMMUNOLOGY; SERODIAGNOSIS; SEROTYPE; VIROLOGY; ZIKA FEVER;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CROSS REACTIONS; DENGUE; DENGUE VIRUS; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; SEROGROUP; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85018639002     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2305.161630     Document Type: Article

References (46)

1. Lazear HM, Diamond MS. Zika virus: new clinical syndromes and its emergence in the Western Hemisphere. J Virol. 2016;90:4864–75. http://dx.doi.org/10.1128/JVI.00252-16
2. Smith DW, Mackenzie J. Zika virus and Guillain-Barré syndrome: another viral cause to add to the list. Lancet. 2016;387:1486–8. http://dx.doi.org/10.1016/S0140-6736(16)00564-X
3. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastere S, Valour F, et al. Zika virus infection complicated by Guillain-Barré syndrome—case report, French Polynesia, December 2013. Euro Surveill. 2014;19:20720. http://dx.doi.org/10.2807/1560-7917. ES2014.19.9.20720
4. Moreira J, Peixoto TM, Machado De Siqueira A, Lamas CC. Sexually acquired Zika virus: a systematic review. Clin Microbiol Infect. 2017 Jan 3 [Epub ahead of print]. pii: S1198-743X(16)30659-0. http://dx.doi.org/10.1016/j.cmi.2016.12.027
5. Miranda-Filho DB, Martelli CM, Ximenes RA, Araújo TV, Rocha MA, Ramos RC, et al. Initial description of the presumed congenital Zika syndrome. Am J Public Health. 2016;106:598–600. http://dx.doi.org/10.2105/AJPH.2016.303115
6. Coyne CB, Lazear HM. Zika virus—reigniting the TORCH. Nat Rev Microbiol. 2016;14:707–15. http://dx.doi.org/10.1038/nrmicro.2016.125
7. Castanha PMS, Cordeiro MT, Martelli CM, Souza WV, Marques ET Jr, Braga C. Force of infection of dengue serotypes in a population-based study in the northeast of Brazil. Epidemiol Infect. 2013;141:1080–8. http://dx.doi.org/10.1017/S0950268812001367
8. World Health Organization. Dengue vaccine: WHO position paper—July 2016. Wkly Epidemiol Rec. 2016;91:349–64.
9. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14:1232–9. http://dx.doi.org/10.3201/eid1408.080287
10. Allwinn R, Doerr HW, Emmerich P, Schmitz H, Preiser W. Cross-reactivity in flavivirus serology: new implications of an old finding? Med Microbiol Immunol (Berl). 2002;190:199–202. http://dx.doi.org/10.1007/s00430-001-0107-9
11. Mansfield KL, Horton DL, Johnson N, Li L, Barrett AD, Smith DJ, et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol. 2011;92:2821–9. http://dx.doi.org/10.1099/vir.0.031641-0
12. Crill WD, Chang G-JJ. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004;78:13975–86. http://dx.doi.org/10.1128/JVI.78.24.13975-13986.2004
13. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis. 2011;5:e1188. Erratum in: PLoS Negl Trop Dis. 2011;5(8). http://dx.doi.org/10.1371/journal.pntd.0001188
14. Kostyuchenko VA, Lim EX, Zhang S, Fibriansah G, Ng TS, Ooi JS, et al. Structure of the thermally stable Zika virus. Nature. 2016;533:425–8.
15. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, et al. Structural basis of potent Zika–dengue virus antibody cross-neutralization. Nature. 2016;536:48–53. Erratum in: Nature. 2016;539:314.
16. Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113:7852–7.
17. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353:823–6. http://dx.doi.org/10.1126/science.aaf8505
18. Swanstrom JA, Plante JA, Plante KS, Young EF, McGowan E, Gallichotte EN, et al. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. MBio. 2016;7:e01123-16. http://dx.doi.org/10.1128/mBio.01123-16
19. Zhao H, Fernandez E, Dowd KA, Speer SD, Platt DJ, Gorman MJ, et al. Structural basis of Zika virus–specific antibody protection. Cell. 2016;166:1016–27. http://dx.doi.org/10.1016/j.cell.2016.07.020
20. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46: 509–20. http://dx.doi.org/10.1016/0035-9203(52)90042-4
21. Haddow AD, Schuh AJ, Yasuda CY, Kasper MR, Heang V, Huy R, et al. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS Negl Trop Dis. 2012;6:e1477. http://dx.doi.org/10.1371/journal.pntd.0001477
22. Baronti C, Piorkowski G, Charrel RN, Boubis L, Leparc-Goffart I, de Lamballerie X. Complete coding sequence of Zika virus from a French Polynesia outbreak in 2013. Genome Announc. 2014;2:e00500-14. http://dx.doi.org/10.1128/genomeA.00500-14
23. Lanciotti RS, Lambert AJ, Holodniy M, Saavedra S, Signor LC. Phylogeny of Zika virus in Western Hemisphere, 2015. Emerg Infect Dis. 2016;22:933–5. http://dx.doi.org/10.3201/eid2205.160065
24. Brien J D, Lazear HM, Diamond MS. Propagation, quantification, detection, and storage of West Nile virus. Curr Protoc Microbiol. 2013;31:15D.3.1–15D.3.18.
25. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, et al. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J Virol. 2006;80:12149–59. http://dx.doi.org/10.1128/JVI.01732-06
26. Henchal EA, Gentry MK, McCown JM, Brandt WE. Dengue virus–specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg. 1982;31:830–6.
27. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A. 2012;109:7439–44. http://dx.doi.org/10.1073/pnas.1200566109
28. Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, et al. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. MBio. 2015;6:e01461–15. http://dx.doi.org/10.1128/mBio.01461-15
29. de Alwis R, de Silva AM. Measuring antibody neutralization of dengue virus (DENV) using a flow cytometry–based technique. Methods Mol Biol. 2014;1138:27–39. http://dx.doi.org/10.1007/978-1-4939-0348-1_3
30. Kraus AA, Messer W, Haymore LB, de Silva AM. Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol. 2007;45:3777–80. http://dx.doi.org/10.1128/JCM.00827-07
31. Putnak R, Barvir DA, Burrous JM, Dubois DR, D’Andrea VM, Hoke CH, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis. 1996;174:1176–84. http://dx.doi.org/10.1093/infdis/174.6.1176
32. Maeda A, Maeda J. Review of diagnostic plaque reduction neutralization tests for flavivirus infection. Vet J. 2013;195:33–40. http://dx.doi.org/10.1016/j.tvjl.2012.08.019
33. Wahala WMPB, de Silva AM. The human antibody response to dengue virus infection. Viruses. 2011;3:2374–95. http://dx.doi.org/10.3390/v3122374
34. Faria NR, Azevedo RS, Kraemer MU, Souza R, Cunha MS, Hill SC, et al. Zika virus in the Americas: early epidemiological and genetic findings. Science. 2016;352:345–9. http://dx.doi.org/10.1126/science.aaf5036
35. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16:170–7. http://dx.doi.org/10.1038/ni.3058
36. Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. J Infect Dis. 2015;211:590–9. http://dx.doi.org/10.1093/infdis/jiu481
37. Crump JA, Gove S, Parry CM. Management of adolescents and adults with febrile illness in resource limited areas. BMJ. 2011;343:d4847. http://dx.doi.org/10.1136/bmj.d4847
38. Bogoch II, Brady OJ, Kraemer MU, German M, Creatore MI, Brent S, et al. Potential for Zika virus introduction and transmission in resource-limited countries in Africa and the Asia-Pacific region: a modelling study. Lancet Infect Dis. 2016;16:1237–45. http://dx.doi.org/10.1016/S1473-3099(16)30270-5
39. Food and Drug Administration. FDA warns health care providers against relying solely on Zika virus serological IgM assay results; reminds them to wait for confirmatory test results before making patient management decisions [cited 2017 Jan 20]. https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm534515.htm
40. Centers for Disease Control and Prevention. Guidance for US laboratories testing for Zika virus infection [cited 2017 Jan 22 ]. https://www.cdc.gov/zika/laboratories/lab-guidance.html
41. Rabe IB, Staples JE, Villanueva J, Hummel KB, Johnson JA, Rose L, et al.; MTS. Interim guidance for Interpretation of Zika virus antibody test results. MMWR Morb Mortal Wkly Rep. 2016;65:543–6. http://dx.doi.org/10.15585/mmwr.mm6521e1
42. Landry ML, St George K. Laboratory diagnosis of Zika virus infection. Arch Pathol Lab Med. 2017;141:60–7. http://dx.doi.org/10.5858/arpa.2016-0406-SA
43. Wilder-Smith A, Gubler DJ. PUBLIC HEALTH. Dengue vaccines at a crossroad. Science. 2015;350:626–7. http://dx.doi.org/10.1126/science.aab4047
44. Paulke-Korinek M, Kollaritsch H, Kundi M, Zwazl I, Seidl-Friedrich C, Jelinek T. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. Vaccine. 2015;33:3600–4. http://dx.doi.org/10.1016/j. vaccine.2015.05.037
45. Wittermann C, Izu A, Petri E, Gniel D, Fragapane E. Five year follow-up after primary vaccination against tick-borne encephalitis in children. Vaccine. 2015;33:1824–9. http://dx.doi.org/10.1016/j.vaccine.2015.02.038
46. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434–44. PubMed http://dx.doi.org/10.4269/ajtmh.13-0264